Is Intec Pharma Ltd. (NasdaqCM: NTEC) worth a look with an ERP5 of 15524?



The ERP5 Rank is an investment tool that analysts use to discover undervalued companies. The ERP5 looks at the ratio between price / books, profit, ROIC and average ROIC for 5 years. The ERP5 from Intec Pharma Ltd. (NasdaqCM: NTEC) is 15524. The lower the ERP5 rank, the more a company is undervalued.

Investors hope that they will not have to deal with stock selections that do not come true, but this happens fairly often on the stock market. At some point, the investor may have to make the difficult decision to sell a stock that had a lot of upside potential. Sticking to a poorly performing stock can sometimes damage the wallet. Investors may hesitate to let the stock go long after it should have been sold. Following the underlying fundamentals can help the investor to find the right time to buy or sell a particular stock. Mastering this aspect of investing can come with experience, but it can be very beneficial for the long-term success of the portfolio.

Q.i. Value

The Q.i. The value of Intec Pharma Ltd. (NasdaqCM: NTEC) is 93.00000. The Q.i. Value is another useful tool in determining whether a company is undervalued or not. The Q.i. The value is calculated using the following ratio & # 39; s: EBITDA yield, profit yield, FCF yield and liquidity. The lower the Q.i. value, the more undervalued the company is deemed to be.

The EBITDA revenue is a great way to determine the profitability of a company. This number is calculated by dividing the income of a company by interest, taxes, depreciation and amortization by the enterprise value of the company. Enterprise value is calculated by taking the market capitalization plus debts, minority interests and preference shares, less the total cash and cash equivalents. The EBITDA return for Intec Pharma Ltd. (NasdaqCM: NTEC) is -0.469390.

The profit on course of Intec Pharma Ltd. (NasdaqCM: NTEC) is -0.298336. This is calculated by taking the earnings per share and dividing them by the last closing price of the share. This is one of the most popular methods that investors use to evaluate the financial performance of a company. Profit The interest is calculated by taking the operating result or the profit before interest and taxes (EBIT) and dividing it by the enterprise value of the company. The profit for Intec Pharma Ltd. NasdaqCM: NTEC is -0.479644. Profit yield helps investors measure the return on investment for a particular company. Similarly, the five-month average revenue is the five-yearly average operating result or EBIT divided by the current value in use. The Earnings Yield Five Year average for Intec Pharma Ltd. is -0.077228.

FCF Yield 5yr Av

The FCF yield 5-year average is calculated by taking the five-year average free cash flow of a company and dividing it by the current company value. Enterprise value is calculated by taking the market capitalization plus debts, minority interests and preference shares, less the total cash and cash equivalents. The average FCF of a company is determined by looking at the money generated by the company's activities. Free cash flow yield 5 year average from Intec Pharma Ltd. (NasdaqCM: NTEC) is -0.075945.

Price to book, Price to cash flow, Price to earnings

The price / book ratio is the current share price of a company divided by the book value per share. The price / book ratio for Intec Pharma Ltd. NasdaqCM: NTEC is 1.804019. A lower price / book ratio indicates that the shares may be undervalued. Similarly, the price / cash flow ratio is another useful ratio when determining the value of a company. The price cash flow for Intec Pharma Ltd. (NasdaqCM: NTEC) is -3.972143. This ratio is calculated by dividing the market value of a company by cash from operational activities. In addition, the price / earnings ratio is another popular way for analysts and investors to determine the profitability of a company. The price / profit ratio for Intec Pharma Ltd. (NasdaqCM: NTEC) is -3.351928. This ratio is found by taking the current share price and dividing it by the earnings per share.

Value Comp 1 / Value Comp 2

The Value Composite One (VC1) is a method that investors use to determine the value of a company. The VC1 from Intec Pharma Ltd. (NasdaqCM: NTEC) is 84. A company with a value of 0 is considered an undervalued company, whereas a company with a value of 100 is considered an overvalued company. The VC1 is calculated on the basis of book value, price to sales, EBITDA to EV, price to cash flow and price to profit. Similarly, the Value Composite Two (VC2) is calculated with the same ratio, but the Shareholder Yield is added. The Value Composite Two from Intec Pharma Ltd. (NasdaqCM: NTEC) is 90.

Volatility 12 m, 6 m, 3 m

Stock volatility is a percentage that indicates whether a share is a desired purchase. Investors look at the volatility 12m to determine whether a company has a low volatility rate or not in the course of a year. The volatility 12 m of Intec Pharma Ltd. (NasdaqCM: NTEC) is 60.147100. This is calculated by taking weekly log normal returns and standard deviation of the share price over a year on an annual basis. The lower the number, a company is assumed to have low volatility. The volatility 3m is a similar percentage determined by the daily normal logbook yield and the standard deviation of the share price during 3 months. The volatility 3m of Intec Pharma Ltd. (NasdaqCM: NTEC) is 33.102700. The volatility 6m is the same, except measured over the course of six months. The volatility 6m is 41.659800.

MF Rank

The MF Rank (also known as the Magic Formula) is a formula that traces a valuable company for a good price. The formula is calculated by looking at companies with a high profit return and a high return on invested capital. The MF rankings of Intec Pharma Ltd. (NasdaqCM: NTEC) is 18041. A low-ranking company is considered a good company to invest in. The magic formula was introduced in a book written by Joel Greenblatt entitled "The Little Book that beats the market".

Piotroski F score

The Piotroski F-Score is a scoring system between 1-9 that determines the financial strength of a company. The score helps determine whether the shares of a company are valuable or not. The Piotroski F-score from Intec Pharma Ltd. (NasdaqCM: NTEC) is 2. A score of nine indicates a high value, while a score of nine indicates a stock with a low value. The score is calculated by the return on assets (ROA), the cash flow return on assets (CFROA), the change in the return on assets and the quality of the income. It is also calculated by a change in gearing or leverage, liquidity and change in issued shares. The score is also determined by the change in the gross margin and the change in the turnover of assets.

Return on assets

There are many different tools to determine whether a company is profitable or not. One of the most popular ratio is the & # 39; Return on Assets & # 39; (also known as ROA). This score indicates how profitable a company is in relation to its total assets. The return on assets of Intec Pharma Ltd. (NasdaqCM: NTEC) is -1,610,676. This number is calculated by dividing the net result after tax by the total assets of the company. A company that manages its assets well has a higher return, while a company that manages its assets poorly will have a lower return.


Source link

Leave a Reply